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The advent of cost-effective genotyping and sequencing methods have recently made it possible to
ask questions that address the genetic basis of phenotypic diversity and how natural variants
interact with the environment. We developed Camelot (CAusal Modelling with Expression Linkage
for cOmplex Traits), a statistical method that integrates genotype, gene expression and phenotype
data to automatically build models that both predict complex quantitative phenotypes and identify
genes that actively inﬂuence these traits. Camelot integrates genotype and gene expression data,
both generated under a reference condition, to predict the response to entirely different conditions.
We systematically applied our algorithm to data generated from a collection of yeast segregants,
using genotype and gene expression data generated under drug-free conditions to predict the
response to 94 drugs and experimentally conﬁrmed 14 novel gene–drug interactions. Our approach
is robust, applicable to other phenotypes and species, and has potential for applications in
personalized medicine, for example, in predicting how an individual will respond to a previously
unseen drug.
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Introduction
Understanding how differences in genotype account for the
wide range of phenotypic diversity between individuals is one
of the fundamental challenges of biology. With the advent of
high-throughput sequencing, the number of available geno-
types is increasing at a staggering rate, and we are nearing the
point where DNA sequence represents individuals rather than
organisms, providing a toehold towards answering this
question. Most traits are determined by multiple genes whose
identities are largely unknown; therefore, the challenge of
predicting an individual’s phenome (i.e., spectrum of traits)
from its genome requires both identiﬁcation of the genes that
inﬂuence the trait, and models that describe how they interact
to determine the trait (Gabriel et al, 2002; Maller et al, 2006).
Our approach is to combine genotype and gene expression
data to associate genetic factors with the downstream changes
in phenotype. Our premise is that gene expression is useful
because it integrates information from multiple loci that are
individually too weak to detect but which, in combination,
contribute signiﬁcantly to the phenotype. Gene expression has
provenapotentpredictorofphenotype,mostnotablyincancer
genomics, where gene expression is used to build classiﬁers
that predict response to therapy (Alizadeh et al, 2000; van’t
Veer et al, 2002; Kutalik et al, 2008). While relatively accurate,
these predictors typically consist of 4100 genes and do not
provide mechanistic insight regarding the genes responsible
for this response. Ground breaking approaches in the genetics
of gene expression (Brem et al, 2002; Cheung and Spielman,
2002; Dixon et al, 2007) have recently been used to show that
gene expression can be used to associate genes with disease
phenotypes (Mehrabian et al, 2005; Schadt et al, 2005; Chen
et al,2008;Emilsson etal,2008);however,thesemethods only
identify the genes involved and do not directly predict multi-
gene traits from the genotype.
We developed Camelot (CAusal Modelling with Expression
Linkage for cOmplex Traits) and applied it to genotype, gene
expression and phenotype (growth in thepresence of drug) data
from segregants obtained from a cross between two diverse
strains of Saccharomyces cerevisiae (Brem and Kruglyak, 2005;
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manifest in rich phenotypic diversity in the segregants. To our
knowledge, Camelot is the ﬁrst method that automatically
builds a model based on both gene expression and genotype,
selects genes that actively inﬂuence the phenotype and
accurately predicts complex quantitative phenotypes. Having
‘trained’ a model, we can use it to accurately predict the
growthofanewstrainwithanentirelydifferentgenotype.This
is demonstrated by correctly predicting growth, in the
presence of each of a panel of drugs, for segregants not used
during training. Most importantly, the majority of genes used
for predicting growth are causal factors. Thus, genetic
manipulation of these genes (deletion or allele swap, that is,
replacement of the causal gene with the same gene from the
other parental strain) leads to a change in phenotype (e.g.,
drug resistance/sensitivity) matching our prediction.
An important distinguishing feature of Camelot is that it
integrates genotype and gene expression data, generated
under drug-free conditions, to detect causal genes and predicts
the response to an entirely different condition, growth in the
presenceofadrug.Therefore,geneexpressionofanindividual
need only be assayed once. This single-gene expression proﬁle
can be harnessed to analyse the connection between genotype
and phenotype for a large number of traits that manifest under
many different conditions. Moreover, the response to a drug
can be predicted before treatment, a critical feature for clinical
application.
Our results demonstrate that Camelot can predict a strain’s
response to a drug, for 87/94 drugs. The inclusion of gene
expression data measured under unrelated (drug-free) condi-
tions signiﬁcantly contributes to Camelot’s accuracy in
predicting drug response and in its ability to detect causal
genes involved in this response. We experimentally conﬁrmed
25/27 of Camelot’s predictions regarding the inﬂuence of a
speciﬁc gene in the response to a speciﬁc drug. Our data
demonstrate that Camelot is able to identify genes involved in
drug resistance robustly.
Results
We used a data set containing information from 104 segregants
that arose from the mating of two genetically diverse strains,
‘BY’ and ‘RM’ (Brem and Kruglyak, 2005). The data include
the growth yield from each segregant grown in the presence of
one of 94 chemicals (‘drugs’) (Perlstein et al, 2007), 526
processed markers denoting genotype (Lee et al, 2006) and
6189 gene expression proﬁles, measured in rich media, for
each segregant (Brem and Kruglyak, 2005).
The BY and RM strains used in this study are genetically
distant,with0.5%sequencediversitybetweenthem.Thisgenetic
diversity manifests in signiﬁcant phenotypic diversity. Not only
do the strains differ in their response to drugs; each drug has a
different set of fast- and slow-growing segregants (Box 1A).
Gene expression measured in the absence of drug
helps predict drug response
Our goal is to obtain baseline information about a strain,
genotype and gene expression data measured from each
segregantgrownintheabsenceofdrug,andusethistoderivea
quantitative prediction of the strain’sphenome, its response to
each drug in a panel of drugs. We seek to identify a small set of
features, either genotypic markers or single genes (transcripts
in the gene expression data) that inﬂuence growth in the
presence of each drug, and to explain the observed differences
between segregants. We use the term ‘causal’ to describe a
feature that not only correlates with and predicts the
phenotype, but which actively inﬂuences it. We deﬁne a
feature as ‘causal’ if genetic manipulation of this feature, for
example, by allele swap or gene deletion, changes the
phenotype, as predicted by the model.
Identifying a predictive model deﬁnes a task of selecting a
sparsesetoffeaturesfromapoolofmarkersandaprecompiled
list of transcripts that together predict growth in the presence
of drug D. Although the true relationship may not be linear,
we use linear models as these can be robustly inferred from
the data (Hastie et al, 2001). Camelot selects a sparse set of
features, markers {L} and transcripts {E} so that DB{L}þ
{E} (Box 1B).
Identifying a small number of predictive features from
thousands of candidates is a well studied problem of high
dimensional feature selection (Hastie et al, 2001). To avoid
identifyingfeaturesthatmatchthetrainingdatabychance,our
algorithm uses a combination of statistical tools including
elastic net regularized regression (Zou and Hastie, 2005), non-
parametric bootstrap (Efron, 1979) and tests designed to
further select only those that are most likely causal. The
selected features are then used to optimise a linear prediction
function (see section Materials and methods).
Weevaluatedtheperformanceofourapproachusing10-fold
cross-validation; we randomly split the segregants (strains)
into training and test sets and completely withheld any data
relating to the test strains during model selection. Camelot
uses gene expression, genotype and drug response data from
strains in the training set to build a model that both predicts
growth for each condition (þdrug) and identiﬁes the genes
responsible for the differences in phenotype between strains.
Camelot was subsequently used to predict the drug response
for the withheld test strains using only genotype and gene
expression data measured under drug-free conditions (see
section Materials and methods). These test strains simulate a
situation in which Camelot is used to predict the phenotype of
new, previously unobserved, strains.
Camelot outperforms association and linkage analysis in
providing a set of features that yield signiﬁcantly more
accurate prediction of drug response (see Figure 1A–D). We
found that Camelot’s predictions for growth in the test strains
were more accurate for 88% of the conditions examined,
comparedwiththoseobtainedusingstandardlinkagemethods
(Figure1A),andinmanycasesledtodramaticimprovementin
the accuracy of prediction, for example, for clomiphene and
haloperidol (Figure 1C and D).
While Camelot’s statistically rigorous feature selection
framework contributes to its success, so does the use of gene
expression data, as evidenced when we compare our method
with and without the use of expression data (Figure 1B–D).
Note that the gene expression data were obtained from cells
grownundernutrient-rich,non-perturbedconditions,whereas
the growth data were measured in the presence of different
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Box 1 (A) Growth in the presence of a subset of drugs is represented by the heat map on the left (blue corresponds to low growth yield and yellow to high growth
yield). Each row represents the data for a single drug (SMP10 is 1,9-pyrazoloanthone, DFI is diphenyliodonium and SK&F is SK&F 96365) and each column
representsadifferentstrain/segregant.Theredrectangleshowstheresponseofasegreganttothesetofdrugsindicated,knownasthe‘phenome’,ofthestrain.The
heatmapontheright representsthecorrelation betweentheresponses ofthesegregantstothe drugs(Pearson’scorrelation coefﬁcient).Therowsandcolumnsare
in the same order as the rows in the heat map on the left. The range in Pearson’s correlation coefﬁcient demonstrates that there is considerable diversity in the
response ofthesegregants tothesedrugs;thecorrelationranges fromstrongpositivecorrelation (r¼0.64)tostrong anticorrelation( 0.40). Thesamescaleisused
for all the ﬁgures. (B) Overview of Camelot. The input data include matched genotype (L) and gene expression (E) data for each segregant measured under
standard conditions (no drug) and growth yield/drug response (D) measured in the presence of a drug. Each column represents a strain/segregant and each row
represents a marker feature in the genotype matrix or a transcript feature in the gene expression matrix. Camelot outputs a predictive regression model with a small
setofmarkersandgeneexpressionfeatures.Inthetrainingphase,Camelottakesgenotype,geneexpressionanddrugresponseasinputandusesfeatureselection
methods (elastic net, bootstrap, the triangle test and model revision) to choose a small set of marker and gene expression features that best predict the drug
response that are enriched for features likely to have a causal inﬂuence on the phenotype. Selected sets of features are denoted by L
Camelot and E
Camelot,
representingselectedmarkersandtranscripts,respectively. Alinearregression modelisthenbuiltonL
CamelotandE
Camelot.Inthepredictionstage,Camelotusesthe
model built on the training data (regression coefﬁcients bLC and bEC) and the genotype and expression data for the held-out segregants to predict growth in the
presence of drug. Following model selection, Camelot takes each selected marker (L
Camelot) and uses the zoom-in score to prioritize the likelihood that each gene
within the linked region is causal.
Box 1 Diversity of drug response and the outline of the Camelot algorithm
Identifying the genetic basis of drug resistance
B-J Chen et al
& 2009 EMBO and Macmillan Publishers Limited Molecular Systems Biology 2009 3drugs and that the expression features chosen differed
between the drugs. Therefore, the features selected are
unlikely to represent genes whose expression merely corre-
lates with rapid growth (Airoldi et al, 2009).
The response of segregants to different conditions is
heritable (Perlstein et al, 2006), so the boost in performance,
over genotype alone, gained by using gene expression data
(generated in the absence of drug) is counter-intuitive
(Figure 1B). A factor that contributes to the accuracy is that
transcript features chosen by Camelot typically correlate well
with the measured growth yield in the presence of a drug.
This success in prediction is similar to the success of
gene-expression-based classiﬁers in predicting response to
chemotherapy in cancer genomics (van’t Veer et al, 2002).
However, correlation does not necessarily imply causality.
Identifying features that actively inﬂuence
the phenotype
Camelot aims to ﬁnd a model that is not only predictive, but
also identiﬁes genes that are responsible for the phenotypic
variation. Identiﬁcation of these genes provides insight into
the biological processes and stresses involved in response to a
drug, and has practical implications for identifying alternative
drug targets in resistant strains.
Care must be taken when attributing a causal interpretation
to a correlated feature, even when the feature acts as a potent
predictor (Pearl, 2000). When the feature correlated with
growth is based on linkage to a DNA marker, the issue of
causality is straightforward: the observed phenotype is likely
inﬂuenced by genetic polymorphism within the linked region.
However,whenthefeatureisbasedoncorrelationbetweenthe
abundance of a transcript and the phenotype, three possibi-
lities exist: (1) the transcript and phenotype correlate due to a
common cause resulting from DNA variation (Figure 2C),
(2) DNA variation exerts its effect on the phenotype through
the gene, and hence the expression level serves as an indicator
of the causal effect of the genetic differences on the phenotype
(Figure 2D) or (3) growth rate inﬂuences the abundance of the
transcript. The last option is not considered in this experi-
mental design, as gene expression was measured in the
absence of drugs.
For example, there are 123 genes whose expression
correlates with growth in hydrogen peroxide with an absolute
coefﬁcient of 0.35 or greater. Of these, Camelot only chose one
transcript feature,DHH1(Figure3A).WeexplainhowCamelot
goesbeyondcorrelationtoidentify themostlikelycausalgene.
First, Camelot limits the set of possible candidate transcript
featuresto854transcriptsthatarenotparticulartoanyspeciﬁc
drug, yet are a priori more likely to be causal based on the
functional classiﬁcation of their cognate genes (see section
Materials and methods). Camelot selects features using a
bootstrap procedure on coefﬁcients of regularized regression
(see section Materials and methods). Systematic evaluation
using synthetic data shows that bootstrapping of regression
Clomiphene at 80 h
No linkage
Elastic L
Camelot
Linkage
r = 0.33
r = 0.69
Growth
Elastic L
Camelot
Linkage
r = 0.72
r = 0.45
r = 0.45
Haloperidol at 55 h
Growth
ΔAcc<0
ΔAcc<0.2
ΔAcc<0.4
ΔAcc0.4
0 0.3 0.6 0.9
0
0.3
0.6
0.9
AB
CD
Accuracy of linkage analysis
A
c
c
u
r
a
c
y
 
o
f
 
C
a
m
e
l
o
t
0 0.3 0.6 0.9
0
0.3
0.6
0.9
Accuracy of elastic L
A
c
c
u
r
a
c
y
 
o
f
 
C
a
m
e
l
o
t
P
r
e
d
i
c
t
i
o
n
P
r
e
d
i
c
t
i
o
n
Figure 1 Camelot has superior predictive ability. Comparison of prediction methods on held out test data from different models. (A) Classiﬁcation accuracy (see
section Materials and methods): Camelot compared with linkage analysis. Each dot represents a condition (growth yield in the presence of a drug), showing the fraction
correctly predicted by Camelot (y-axis) and linkage analysis (x-axis). Dots above the diagonal indicate the superior performance of Camelot and are colour coded to
indicate the degree of improvement. (B) As in panel A, but the classiﬁcation accuracy by Camelot is compared with that of the elastic-net L model lacking transcript
features (see section Materials and methods). This demonstrates that for many conditions the inclusion of gene expression features improves Camelot’s performance.
(C) The top bar represents growth in the presence of clomiphene; each column is associated with a different segregant (matched horizontal positions within the panel)
sorted by growth from low (blue) to high (yellow). The observed growth is compared with model prediction from linkage analysis, the elastic-net L model and Camelot.
The bar marked elastic L represents predictions from bootstrapped elastic net regression using genotype alone, and the bottom bar represents prediction from Camelot.
Prediction(ontestdata)improvesfromnodetectedlinkagetomostaccurateforCamelot.Thesamescaleisusedforalltheﬁgures.(D)AsinpanelC,butforhaloperidol.
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pointing the causal features that generate the phenotype, both
compared with elastic net regression alone and the feature
selection methods used by Schadt et al (2005) and Chen et al
(2008) (Supplementary Figure 1). For the hydrogen peroxide
response, GO-based ﬁltering reduced the list of 123 candidate
transcripts to the 15 genes shown in Figure 2A. Bootstrapping
further reduced the list of expression features to a single gene,
DHH1, that was subsequently experimentally validated
(Figure 3C).
In the next stage, Camelot explicitly tests for causality. We
apply a causality test to all transcript features chosen with
signiﬁcant conﬁdence after bootstrapping. The permutation-
based triangle test asks, ‘Is gene expression signiﬁcantly
predictive of the growth beyond the contribution of the linked
genotype?’ (Figure2B and section Materials and methods). We
assume that the linked DNA marker is causative a priori and
require that the transcript feature remains signiﬁcantly
predictive of growth even after the inﬂuence of the marker is
controlled for. While this test does not guarantee that the
transcript feature is indeed causal, it identiﬁes transcript
features that are more likely causal and enriches the ﬁnal
selection with causal features. For example, the abundance of
the DHH1 transcript was selected by our bootstrap procedure
as a feature that predicted the response to 10 different drugs.
After administering the triangle test, DHH1 passed as causal
for only six of these drugs. These were subsequently validated
experimentally (Figure 3D). The variability in DHH1 expres-
sion across segregants arises because of polymorphism in
MKT1 (chromosome XIV) (Leeet al, 2009),although it islikely
that other genetic factors also affect DHH1 expression. We
believe that DHH1 expression is inﬂuenced by multiple genetic
factors, that are individually too weak to detect, and that this
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Figure 2 Correlation versus causality. (A) Growth yield in the presence of
hydrogen peroxide and correlated expression proﬁles for genes in the candidate
pool (absolute Pearson correlation coefﬁcients X0.36, Po2 10
 4), showing
that the expression of multiple genes correlates with growth. Each column is
associated with a different segregant (matched horizontal position across panel)
sortedbygrowthyield(asinFigure1)andgeneexpressiononared–greenscale.
(B) The triangle test evaluates the likelihood that each transcript feature causally
explains the phenotype (red edge). It distinguishes between causal chain (left,
red edge) and co-regulation structures (right, grey edge) using permutation
testing to evaluate the contribution of gene expression controlled for the
genotype of L. That is, expression is permuted under the allele of the linked
genotype (see section Materials and methods). Orange represents RM and blue
BY for the genotype at the locus. Some notation for all the ﬁgures: Blue ovals
represent the genotype of a marker; yellow ovals, drug response; green ovals,
gene expression; red arrows, the driving edge; black arrows, causal relationships
and grey arrows, relationships tested in the test. Red letters indicate the type of
the selected feature (expression in this case). (C) Sequence variation at
Chromosome XIV locus is the cause of variation in both DHH1 expression and
the response to lycorine; however, in this situation DHH1 expression does not
causally inﬂuence the drug response. DHH1 was a candidate feature for lycorine
(correlation coefﬁcient, r¼0.44), but failed the triangle test, showing that high
correlation does not necessarily reﬂect causality. The heat maps show
segregants ordered based on response to lycorine. (D) Example of a causal
chainwherepolymorphismsataChromosomeXIVlocusleadtochangeinDHH1
expression that results in differences in cell growth in the presence of H2O2.
DHH1 was chosen as a candidate feature for H2O2 (r¼ 0.44) and passed the
triangle test with P-value 1.6 10
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Figure 3 Causal role of DHH1.( A) Growth yield in the presence of H2O2
compared with model prediction from linkage analysis, elastic-net L model and
Camelot, represented as in Figure 1C, demonstrating superior prediction by
Camelot. Camelot chose a Chromosome XIII locus (227254–243624) and
expression ofDHH1 asfeatures to predict the drugresponse; the values for each
segregant are represented in the same order within the panel. (B) The full
prediction function obtained from Camelot for response to H2O2. DHH1 is
selected as a feature and conﬁrmed by the triangle test; the Chromosome XIII
marker is selected as a feature and the zoom-in score identiﬁes ERG6 as the
causal gene within the region, ﬁtting with reports that overexpression of ERG6
leads to decreased resistance to hydrogen peroxide (Khoury et al, 2008). The
Chromosome XIV locus is at position 449639–486861. Some notation for all the
ﬁgures: Green rectangles (such as ERG6) represent expression of a gene within
a linked region. (C) Averaged OD600 absorbance growth measurements of BY
(red) andBY dhh1D mutant (blue) plotted against twofold dilution series of H2O2.
The error bars represent the standard error of the mean for all growth yield data.
These data conﬁrm the causal effect of DHH1.( D) DHH1 is a hub passing the
triangletestforsixdrugs(leftcolumn).Fiveoftheseweretested;validatedcausal
effects are in green, with one false positive listed in red. To assess the drug
speciﬁcity of DHH1-mediated effects, four negative controls were tested (right
column); conﬁrmed negative predictions are listed in green and one false
negative in red. See Supplementary Figure 2 for drug response curves for each
of the drugs tested, as represented in Figure 3C.
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prediction accuracy.
From prediction to mechanism
The true value of gene expression comes to light when one
focuses not on how resistant a strain is, but rather why it is so.
Ratherthan being ablackboxpredictor,transcriptfeaturescan
help shed light on the mechanisms underlying resistance.
DHH1 was chosen as a feature for a large number of drugs, so
wetestedCamelot’spredictionthatDHH1playsacausalrolein
mediating resistance to these drugs. DHH1 expression is
negatively correlated with growth in the presence of hydrogen
peroxide (correlation coefﬁcient r¼ 0.44), and we tested the
prediction that DHH1 inﬂuences drug response by measuring
the growth yield of wild-type and dhh1D strains in hydrogen
peroxide (Figure 3C and section Materials and methods). The
dhh1D strain grew better than the wild type, conﬁrming that
DHH1 negatively inﬂuences the phenotype.
This result complements the ﬁnding that Dhh1 colocalizes
with the sequence-speciﬁc RNA-binding protein Puf3 and
regulates the abundance of 153 Puf3-bound mRNAs (Lee et al,
2009). Puf3 is a factor that binds select nuclear-encoded genes
involved in mitochondrial biogenesis and likely regulates the
transport/translation/stability of these messages (Garcia-
Rodriguez et al, 2007; Saint-Georges et al, 2008). These Puf3-
bound, mitochondrial-related genes are signiﬁcantly upregu-
lated in dhh1D strains (Lee et al, 2009). As DHH1 is expressed
atahigherlevelintheBYparent,thisstrainmighthavealower
capacity for detoxiﬁcation of the reactive oxygen species
produced on hydrogen-peroxide treatment and a lesser ability
to withstand this insult. Genes annotated for mitochondria
are upregulated in the RM strain (Litvin et al, 2009) and this
strain is predisposed towards respiratory growth (Smith and
Kruglyak, 2008).
Testing the causal role of transcript features
We conﬁrmed our predictions for the inﬂuence of DHH1 on
growth in totarol, valinomycin, hydrogen peroxide and
triﬂuoperazine. Benzethoniumchloride was the only false
positive among the drugs tested (Figure 3D and Supplemen-
tary Figure 2). We included lycorine, hinokitiol, hexylresorci-
nol and tamoxifen as negative controls to demonstrate that
DHH1 activity is drug speciﬁc. Only growth in tamoxifen was
inﬂuencedbyDHH1;indeedtamoxifenperturbsmitochondrial
function (Tuquet et al, 2000; Cardoso et al, 2001). This
demonstrates the stringency of our approach, which is
designed to minimize false positives and does not detect all
genes that inﬂuence drug responsiveness or all drugs
inﬂuenced by a gene. In summary, we conﬁrmed 4/5 of the
positive predictions tested and 3/4 of the negative predictions
for DHH1, demonstrating the drug speciﬁcity of our predic-
tions. Although the drugs linked to DHH1 are diverse and
include an antibiotic (valinomycin) and an antipsychotic drug
(triﬂuoperazine), they all affect mitochondrial function
(Nicolson et al, 1999; Evans et al, 2000; Nulton-Persson and
Szweda, 2001; Lee et al, 2005; Saﬁulina et al, 2006; Yip et al,
2006; Sancho et al, 2007; Lee et al, 2008). This suggests a
possible application of Camelot in predicting the mechanism
of action of novel drugs.
MGA2, a gene whose product is involved in fatty-acid
metabolism (Chellappa et al, 2001; Jiang et al, 2002;
Kandasamy et al, 2004), was identiﬁed as another transcript
feature predictive of growth for six drugs. Three of these
(cerulenin, ikarugamycin and tomatine) act by perturbing
processes involved in fatty-acid and lipid synthesis and
membrane permeability (Vance et al, 1972; Hasumi et al,
1992; Friedman, 2002). Unsaturated fatty acids (FA) are
essential components of membranes and FA synthesis is
effected by controlling the stability of OLE1 mRNA. Ole1 is
required for the formation of monounsaturated FA precursors
(Martin et al, 2007). Mga2 acts to stabilize or destabilize the
OLE1 message depending on the conditions (Kandasamy et al,
2004). The gene expression data show that in the non-
perturbed state MGA2 expression is negatively correlated with
OLE1 expression (r¼ 0.54) and positively correlated with the
drug response.
These examples illustrate the power of Camelot to identify
genes that causally inﬂuence the response to multiple drugs,
predict the mechanism of action of drugs and provide insight
into the underlying biology.
Using gene expression to identify causal genes
within a linked region
Transcript features relate to a single gene and hence directly
identify the involved gene. DNA marker features are better
founded in their causal nature, but typically involve large
chromosomal regions containing tens of genes. For these
features, Camelot uses gene expression to help pinpoint the
causal gene within the linked locus. The zoom-in score uses
gene expression to prioritize the likelihood that each gene
within the linked region is causal. Like the triangle test, the
zoom-in score is a measure of how well gene expression
predicts the phenotype. Linkage implies that the marker is
driving the causality; therefore, the zoom-in score includes an
additional measure for cis-linkage, how well the marker
predicts the gene expression. The zoom-in score incorporates
both of these qualities, as well as conservation of the protein
sequence to prioritize genes within a locus (see Figure 4A and
section Materials and methods).
Camelot chose two features for hydrogen peroxide, the
DHH1 transcript and a region on chromosome XIII (locus
227254–243624) containing 88 genes (Figure 3B). The zoom-
in score identiﬁed ERG6 as the causal gene within this region,
that is, polymorphism in the ERG6 sequence between the BY
and RM strains is likely responsible for the differences in the
response to hydrogen peroxide between the parent strains.
Overexpression of ERG6 leads to decreased resistance to
hydrogen peroxide (Khoury et al, 2008), matching Camelot’s
prediction (Figure 3B). These results demonstrate how the
triangle test and zoom-in score combine to provide a better
understanding of the cellular response to each drug.
Similar to linkage analysis (Perlstein et al, 2007), Camelot
identiﬁed the two largest marker hotspots, a region on
chromosome XIII (locus 27644–33681), linked to 25 drugs,
and a region on chromosome XIV (linked to 12 drugs). While
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the zoom-in score further identiﬁed PHO84 (chromosome
XIII), as the top-ranked causal variant for multiple drugs. Two
of these drugs, tetrachloroisophthalonitrile and pentachlor-
ophenol, were manually identiﬁed and veriﬁed previously
(Perlstein et al, 2007). PHO84 was top scored for a number of
additional drugs linking to the chromosome XIII hotspot, but
scored poorly for other drug phenotypes linking to this
hotspot. We used the zoom-in score to distinguish which
drugs are causally inﬂuenced by PHO84 and validated these
predictions by growing wild-type BYand allele-swapped (AS)
strains (BY strain containing PHO84 with one amino-acid
substitution, L259P, from the RM strain) individually in the
presence of one of nine drugs. We included drugs with both
positive and negative predictions. Camelot correctly predicted
bothpositiveandnegativeresponses9/9times,demonstrating
that the zoom-in score can be used to identify which of the
Chromosome XIII-linked drug phenotypes are causally inﬂu-
enced by the PHO84 allele (Figure 4B–D and Supplementary
Figure 3). We performed a similar analysis for the drugs
linking to the Chromosome XIV region and identiﬁed three
drugslikelytorespondtoMKT1andthreelinkeddrugsthatare
unlikely to be affected by MKT1. Again Camelot correctly
predicted the response to the drugs in an AS (BY MKT1-RM)
strain6/6times (Supplementary Figure4). These datavalidate
our approach and demonstrate that Camelot is also able to
capture factors accounting for phenotypic variation, using
markers as features, for a number of causal genes.
GPB2 a new causal gene for multiple drugs
Both PHO84 and MKT1 have previously been shown to
inﬂuence phenotypic differences between BY and RM,
although Camelot successfully linked four new phenotypes
(response to drug) to PHO84 and three new phenotypes to
MKT1. To further test Camelot, we assessed whether it could
identify new genes, not previously implicated in the differ-
ences between BYand RM. One of the strongest signals from
our zoom-in analysis comes from the locus of Chromosome I:
1–55329, which links to growth under a number of drugs
including haloperidol, E6berbamine and gliotoxin. Segregants
bearing the RM allele are highly sensitive to these drugs. GPB2
is consistently the top-scored gene at this locus for all these
drugs. Sequence alignment showed that GPB2 differs by 10
amino-acid substitutions between BYand RM and that one of
them is highly conserved across fungal species (P269L,
BY-GPB2 encodes proline and RM-GPB2 encodes leucine).
We engineered an AS strain (BY GPB2-RM) in which the entire
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Figure 4 Causal role of PHO84.( A) The zoom-in score for each locus to drug association (red arrow) evaluates the likelihood, P(L, E, D), that each gene in the locus
causally inﬂuences the growth of the strain in response to drug, based on its expression (each row represents a gene at the locus and each column a segregant; see
section Materials and methods for details). (B) Validation of the ability of the zoom-in score to distinguish which drugs are inﬂuenced by PHO84. To the left are high-
scoring drugs predicted to be inﬂuenced by PHO84; all six drugs were validated including two previously associated with PHO84 (Perlstein et al, 2007) (light green) and
fournew drugs associated with PHO84 (dark green). To the right are low-scoring drugs, not expected to be inﬂuenced by PHO84; PHO84 hadno effect on the response
for any of the three, validating the ability of the zoom-in score to make positive and negative predictions. (C) Averaged OD600 absorbance growth measurements of BY
(red) and BY with an allele swap for PHO84-RM (blue) plotted against concentration of doxorubicin. See Supplementary Figure 3 for the response to each drug
represented as in panel C. (D) As panel C, but for tunicamycin, showing that variation in the DNA sequence of PHO84 has little effect.
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strain (see section Materials and methods) and experimentally
validated Camelot’s prediction that GPB2 plays a causal role in
response to these drugs by showing that the BY GPB2-RM
strain is more sensitive to the presence of E6 berbamine,
gliotoxin and haloperidol than the BY strain. Indeed, the AS
strain is highly similar to the RM strain on E6 berbamine and
haloperidol, suggesting that variation in the GPB2 sequence
accounts for much of the difference in the response to these
drugs (Figure 5A).
Gpb2 is an effector of Ga protein Gpa2 and inhibits PKA
downstream of Gpa2, which increases dependence on cAMP
(Harashima et al, 2006; Peeters et al, 2006). Both gliotoxin and
haloperidol affect the cAMP/PKA pathway. Gliotoxin is a
fungicide that increases cAMP/PKA activity (Waring et al,
1997), whereas haloperidol, a clinical antidepressant (dopa-
mine D2 receptorantagonist), increases cAMP/PKA activity in
striatum(Kanekoetal,1992;Turalbaetal,2004).Theseresults
support our ﬁnding that polymorphism in GPB2 has an effect
on the response to these drugs, and suggest that the
mechanism of action involves G-protein signalling. Our
ﬁndings suggest that E6 berbamine, whose pharmacological
effect remains unknown, may also have similar effect on the
cAMP/PKA pathway.
The response to haloperidol is highly variable among
segregants. Although the mechanism of action could not be
established based on linkage to a large region alone, Camelot
provided clues by zooming in on GPB2 and PHO84. These
genes were subsequently validated as causal for the drug
response phenotype (Figure 5B). We assessed the combined
inﬂuence of both genes for growth under haloperidol
statistically, using data from the segregants. Strains carrying
both RM-PHO84 and BY-GPB2 grow better than strains with
other combinations of alleles (Figure 5C), indicating that
PHO84 and GPB2 may function through a common pathway.
The involvement of Pho84 as a sensor and signalling molecule
for phosphate-based activation of PKA (Giots et al, 2003)
furtherimplicatesPKAfunctionintheresponsetohaloperidol.
PHO84 gene expression and feedback
In total, we validated 18/18 predictions made using the zoom-
in score, including 9/9 for PHO84. Although PHO84 has two
SNPs between BY and RM in its coding region, there is no
genetic variation in regulatory regions such as the promoter or
30UTR. Moreover, the AS strain, containing only one amino-
acid substitution (L259P) in the coding region of PHO84 in the
BY background, recapitulated the growth rate of RM for many
of the positive drugs tested. So it is surprising that expression
of PHO84, generated in the absence of any drugs, could
accurately distinguish between drugs that are affected by
PHO84 and those that are not. To better understand why this
information is encoded in the expression data, we carried out
RT–PCR using strains grown in YPD media (no drug) to
monitor PHO84 expression in the BY, RM and the AS (BY
PHO84-RM) strains.
Although the AS strain contains BY cis- and trans-regulatory
factors, the presence of the RM coding region alone (with one
amino-acid substitution L259P) brought the expression of
PHO84 in the AS strain down to that of the RM strain
(Figure 6A). The differencein expression resultsfromnegative
feedback that acts through the Pho84 protein under high-
phosphate conditions (Figure 6B; Wykoff et al, 2007).
To quantify the degree of negative feedback between strains,
we used RT–PCR to measure PHO84 expression under both
low and high-phosphate conditions. As expected, PHO84
expression is signiﬁcantly downregulated under high-phos-
phate, relative to low phosphate, conditions in all three strains
(Figure 6C). Nevertheless, the negative feedback is stronger in
the RM and AS strains (817- and 170-fold change, respectively)
relative to the BY strain that only goes down 11-fold. Under
low-phosphate conditions, the gene expression for all three
strains is similar, suggesting that the loop is not active
(Supplementary Figure 8). This implies that the relative
strength of the negative feedback differs between strains
under the high-phosphate conditions that activate this loop.
We used arsenate, a toxic non-metabolizable phosphate
analogue, as an indicator of the relative afﬁnity of Pho84 for
phosphate. The RM and AS strains are signiﬁcantly more
sensitive to arsenate, suggesting that the RM version of PHO84
is a more efﬁcient transporter of phosphate than the BY strain
(Supplementary Figure 9). This effect is mediated by Pho84 as
addition of methylphosphonate (an inhibitor of Pho84)
reverses this phenotype (data not shown). It is likely that the
differences in Pho84 function between BY and RM are
responsible for the observed differences in drug sensitivity.
Variation in gene expression serves as an indicator of the
variation in protein function, which acts through a feedback
mechanism; the expression level itself is unlikely to be causal
directly.
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Chr XIII
Haloperidol
Chr I
GPB2
BY-GPB2RM
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Figure 5 Causal role of GPB2 in response to drugs. (A) Strains were grown
overnight in YPD medium, diluted to OD600B0.2 and plated with 10-fold dilution
onYPDþdrugmedia(seesectionMaterialsandmethods).Thetopthreepanels
are photos of YPD plates containing DMSO (control), E6 berbamine or gliotoxin.
The bottom panels are photos of YPD plates containing DMSO or haloperidol.
The results show a large difference in drug sensitivity between BY and RM. The
AS strain (BY GPB2-RM) grows at a rate similar to the RM strain. (B) Camelot
identiﬁes two loci (Chromosome I: 1–55329 and Chromosome XIII: 27644–
33681) and causal genes encoded within these loci, GPB2 and PHO84, that
are responsible for the response to haloperidol. (C) Analysis shows that GPB2
and PHO84 interact with each other to inﬂuence growth in the presence of
haloperidol. Shown are the genotypes for PHO84 and GPB2, and growth in the
presence of haloperidol. Segregants with both the PHO84-RM and GPB2-BY
alleles have signiﬁcantly better resistance (P-value from Wilcoxon rank-sum test)
to haloperidol compared with other segregants.
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PHO84 has strong cis-linkage with P-value 6.3 10
 5.W e
therefore asked why PHO84 expression might provide in-
formation beyond that of the presence of the PHO84 allele.
Removing the genome-wide correction for multiple testing in
eQTL, we detect additional regions, each with very weak
linkage(SupplementaryTableV).TheseregionscontainGTR1,
NPP1, PHO85, PHO86 and PHO87, each involved in phosphate
metabolism/transport,that contain multiple non-synonymous
coding SNPs. This suggests that many genes associated
with phosphate metabolism/transport (enrichment P-value
7.4 10
 6; see section Materials and methods) weakly
inﬂuence PHO84 and the expression data represent the
combined inﬂuence of these factors (Figure 6D).
Discussion
We systematically applied Camelot to predict growth of 104
yeast strains in the presence of one of a panel of 94 diverse
drugs. Camelot consistently performed well and successfully
built robust predictive models for 87/94 drugs. It is intriguing
that a single gene expression proﬁle measured in the absence
of any drugs empowered the prediction of traits under novel
conditions (þdrugs) that are dramatically different from the
perturbation-free conditions used for expression proﬁling.
The models constructed by Camelot are not ‘black box’
predictors, but explain the variation in phenotype between the
segregants by identifying the genes that inﬂuence the
phenotype. We use gene expression data to pinpoint causal
variants within large linked regions and to identify genes,
outside linked regions, whose change in expression mediates
the drug response. For each feature type (transcript and
marker) we took the two largest hubs (i.e., a gene associated
with many drugs) and systematically validated Camelot’s
predictions. We also identiﬁed a new causal gene GPB2 and
linked it to a number of drugs including the antidepressant
haloperidol. Twenty-ﬁve out of 27 predictions of causal factors
associated with response to a drug were conﬁrmed, demon-
strating that our method is robust. By incorporating signal
from gene expression, Camelot not only identiﬁes the causal
genes driving the phenotype, but also provides insights into
changes in the underlying regulatory network and the
mechanisms involved. For example, the results from Camelot
suggest a role for mitochondria in response to a number
of drugs.
Identiﬁcation of a transcript feature does not necessarily
mean that the amount of transcript is responsible for the
difference in phenotype between the strains. In the case of
DHH1 (whose coding sequence is identical in BYand RM), it is
likely that a difference in DHH1 expression accounts for
variation in the regulation of mitochondrial biogenesis genes
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Figure6 FeedbackinPHO84expression. (A)Expression levelsofPHO84 intheBY,RMandthePHO84-RM ASstrains. TheexpressionofPHO84in theASandRM
strains issimilarandsigniﬁcantlylowerthan inBY.The folddifferenceiscalculatedrelativetotheBYstrain.Sincethe AS strainonlydiffersfromthe BY straininthe PHO84
coding sequence, feedback regulation must act through the PHO84 gene itself. The error bars represent the s.d. of three replicates. All RT–PCR experiments were
conducted independently at least three times. (B) A negative feedback loop regulates expression of Pho84 in response to the concentration of intracellular phosphate.
When phosphate levels are low, Pho84 is expressed and transports inorganic phosphate into the cell; Pho84 is repressed as intracellular phosphate levels rise.
(C) Expression of PHO84 in SCþhigh-phosphate media compared with that in SCþlow-phosphate media for each strain. The cells were harvested 90min after the
addition of phosphate. The AS and RM strains are repressed to a greater extent than BY in response to the addition of phosphate. (D) Weak eQTL that inﬂuence the
expression of PHO84. These loci are enriched in genes involved in phosphate metabolism and phosphate transport. PHO84 expression links to regions that contain
GTR1, NPP1, PHO84, PHO85, PHO86 and PHO87. The width of arrows corresponds to the signiﬁcance of linkage (P-value for each linkage o0.01; see section
Materials and methods).
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drug response. However, for PHO84, it is likely variation in
Pho84 function that accounts for the differences in drug
sensitivity and that gene expression varies through a feedback
mechanism that ‘reports’ the difference in protein function.
We note that a large number of the detected linkages between
BY and RM involve feedback loops, including AMN1, HAP1,
HAP4 and ZAP1 (Ronald et al, 2005). This could explain why
expression frequently helps in the identiﬁcation of differences
inproteinfunction, including inhuman genetics, wherestrong
cis-eQTLs have been identiﬁed for genes whose cognate
proteins harbour functional variation associated with human
disease, for example, SORT1 associated with lipid metabolism
(Willer et al, 2008) and multiple genes associated with
metabolic traits (Emilsson et al, 2008).
Others have demonstrated the predictive value of gene
expression towards classifying phenotype (Golub et al, 1999;
Alizadeh et al, 2000; van’t Veer et al, 2002; Huang et al, 2007;
Kutalik et al, 2008) and how integrating genotype and gene
expression data could be used to better understand the
relationship between genotype and phenotype in populations
(Mehrabian et al, 2005; Schadt et al, 2005; Chen et al, 2008;
Emilsson et al, 2008). However, to our knowledge, Camelot is
theﬁrstapproachtobothquantitativelypredictphenotypeand
identify genes that causally affect the phenotype. Central to
Camelot is the interplay between causality and predictability;
causal genes are better predictors and good predictors are
more likely to be causal. Optimization of Camelot for both
goals concurrently results in the model’s exceptionally robust
performance across an unprecedented number of complex
traits.
Camelot uses gene expression data generated under control
conditions to predict the phenotype under a new condition.
The additional power gained from gene expression is remark-
able given that the gene expression and genotype data used
here were generated in the absence of drugs, two years before
the generation of the growth (drug) data in another laboratory
(Brem and Kruglyak, 2005; Perlstein et al, 2007). This shows
that our results are based on a robust phenomenon and
represent an inherent characteristic of the segregants. They
are compatible with our work demonstrating that genetic
variation alters cell state and predisposes the segregants
towards different cellular responses (Litvin et al, 2009).
We proposethat gene expression is useful because it integrates
information from multiple loci that are individually too weak
to detect, but which, in combination, contribute signiﬁcantly
to the phenotype (Figure 6D). In this way, the combined
inﬂuence of a large number of weak linkages (many of which
are undetectable) can explain a large part of the heritable
variation and as a consequence, gene expression data,
generated under reference conditions, helps in predicting the
response of segregants to new drugs. Three explanations are
likely; the gene expression data might reﬂect (i) whether the
cell is ‘prepared’ to tolerate a particular type of insult
(Tagkopoulos et al, 2008), (ii) genetic variation in the
regulatory network and the manner in which it is perturbed
in response to the conditions or (iii) genetic variation in
protein function via feedback loops. We expect that one or
more of these explanations describe the situation for distinct
phenotypes, genes and conditions.
Camelot’s integration of genotype and gene expression not
onlyenhancesitsabilitytopinpointcausalgenes,butitcanalso
potentially identify the mechanism of action and the biological
processes involved, thereby expanding the number of drug
targets, for example, by identifying a connection between
Dhh1 and mitochondria. Our method, therefore, has immedi-
ateapplicationforidentifyingalternativeornoveldrugtargets,
for example, in drug-resistant pathogens. Our approach is
highly robust and is applicable to other phenotypes and
species, including humans. For example, genotype and gene
expression data generated from each patient in the non-
perturbed (non-diseased or non-drugged) state prior to the
onset of disease could be used to predict outcomes (positive or
negative responses to a drug or adverse reactions) in response
to the therapeutic interventions under consideration. Acritical
feature is that appropriate drugs/interventions could be
predicted for the healthy individual before a drug is
administered. While the statistical and algorithmic improve-
ment required to accommodate a genome of greater scale and
complexity carries a heavy statistical burden, Camelot
provides another step towards the realization of personalized
medicine, as well as highlighting the power to be gained by
exploiting gene expression data for this application.
Materials and methods
Data and pre-processing
The strain, genotype and gene expression measurements used are
those of Brem and Kruglyak (2005). Growth yields in the presence of
chemicals (‘drug’), consisting of 313 growth conditions (different
concentrationsofchemicalsandtimepoints)and94differentchemical
molecules, were from Perlstein et al (2007). These include genotype,
gene expression and drug response data for 104 strains. We merged
adjacent, highly-correlated markers, to obtain a total of 526 markers
(Lee et al, 2006). For our analysis, we normalized all data to have a
mean of 0 and variance of 1. We compiled a list of candidate gene
expression features based on two sources. One contained genes with
potential regulatory effects, including transcription factors, signalling
molecules, chromatin factors and RNA factors, as described by Lee
et al (2006). The other list included genes involved in vacuolar
transport, endosome, endosome transport and vesicle-mediated
transport, since these functions, or cellular compartments, are
enriched for multi-drug resistance genes (Hillenmeyer et al, 2008).
We combined these two lists and ﬁltered out genes with s.d.p0.2 in
expression level, obtaining 854 expression proﬁles, which were used
as candidate features for all our models. GO categories from http://
www.yeastgenome.org/ were used to associate genes with each
category.
Generation of the GPB2RM AS strain
The mating type of BY4724 was ﬁrst switched to generate HCY413
using a plasmid that expresses HO from a GAL promoter. BY strains
harbouring the GPB2 coding sequence from RM11-1a were generated
using the Delitto Perfetto method of Storici and Resnick (Storici et al,
2003; Storici and Resnick, 2006). The GPB2 coding sequence and
50UTR were sequenced to conﬁrm that the coding sequence of the AS
strainmatchedthatofRM, whereastheupstreamregionremainedthat
of BY. Primers used in this study are listed in Supplementary Table II.
Validation growth experiments
Strains used in this study are listed in Supplementary Table I. The
MKT1-SK1 (D55N) and PHO84 (L259P) AS strains are as described
(Deutschbauer and Davis, 2005; Perlstein et al, 2007). The dhh1D
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and dhh1D growth yield experiments were performed in multi-well
(96- or 384-well) plates as described by Perlstein et al (2007). Serial
dilutions were carried out in replicate and the resulting growth yield
and IC50 values generated using GraphPad Prism (v. 4.01).
For plate assays, overnight cultures of cells were grown in YPD
medium at 301C, diluted to OD600B0.1 and plated at 10-fold dilutions
on YPD plates containing DMSO or DMSOþdrug. Plates were
incubated at 301C or room temperature for 1–2 days for GPB2 or 5
days for the arsenate assay. Final concentrations of drugs were as
described by Perlstein et al (2007). For GPB2: gliotoxin (15.3mM), E6-
berbamine (16.5mM) and haloperidol (66.6mM); for PHO84: arsenate
was used at a ﬁnal concentration of 2mM and methylphosphonate at
10mM as described by Mouillon and Persson (2005).
Outline of the Camelot algorithm
An outline of the Camelot algorithm, including the triangle test and
zoom-in score, is provided here; see Supplementary information for
technical details of the statistical procedures and computational steps.
As input, Camelot is given a matrix X of features by segregants
for two types: (1) Genotypes of genomic markers, L, derived from
SNP microarrays and (2) gene expression data, E, obtained using
microarrays under standard conditions (no drug). Additionally,
Camelot is given a target matrix Y of drugs by segregants; each row
represents D, the response of 104 segregants in the presence of a drug
at a particular dose and time point.
ForeachdrugresponseD,Camelotselectsalinearregressionmodel,
DB{L}þ{E}, involving a small number of selected features ({L} and
{E}). The objective is to select a model that is accurate in its prediction
of D and whosefeatures are likely to have a causal inﬂuence on D, that
is, experimentally altering these features (by allele swap, deletion or
overexpression) inﬂuences the drug response D. The Camelot
algorithm progresses in three steps: feature selection, causality testing
and model reﬁnement.
A biologically plausible model should have a small number of
causal factors with a non-zero weight. To achieve this goal, we use the
elastic net (Zou and Hastie, 2005) regression method to select only the
most signiﬁcant features. Brieﬂy, we solve the optimization problem
^ b ¼ argmin
b
D   Xb jj
2;
subjecttoð1   aÞ b jj 1þab jj
2ptforsomet;
where D represents growth, X is the feature matrix (both D and X are
standardized),b (^ b, the solution)isthevectorof coefﬁcients and aand
t are regularization parameters chosen using a 10-fold cross-validation
procedure. The regularization terms reduce over-ﬁtting the data. The
constraint enforced by the l1 norm assures sparseness of selected
features and l2-norm prevents arbitrary choice of only one out of
several highly correlated features. The latter is especially important in
the gene expression domain, which is abundant in large groups of
highlycorrelated features.To compute the coefﬁcients ^ b, we used least
angle regression (LARS) (Efron et al, 2004).
However, the elastic net target function optimizes only for
prediction error, which is a proxy for the goal of identifying underlying
causal features. Not all predictive features are necessarily causal and
indeed elastic net regression alone yields models with too many
features (Supplementary Figure 5). We further reduce the number of
selected features using non-parametric bootstrap (Efron, 1979).
Indeed, our performance on synthetic data demonstrates that
wrapping elastic net with bootstrapping enhances the precision with
which we identify causal factors (Supplementary Figure 1).
The elastic net and bootstrap procedures are used to generate an
initial small set of high-quality candidate features. For each selected
transcript feature ({E}), we use the triangle test for causality (see
below) to reﬁne our set of selected features. To improve the likelihood
that the ﬁnal feature set contains causal genes, transcript features that
pass the triangle test are kept in the regression and their associated
(genotype) markers are removed, whereas transcript features that fail
the test are removed and replaced with their associated genotype
markers. Once a ﬁnal set of features is selected, regression coefﬁcients
predicting D (response to drug) are re-optimized.
Triangle test
The triangle test is applied to every transcript feature selected and is
used to evaluate the likelihood that the gene is signiﬁcantly predictive
of the response to a drug, beyond the contribution of the linked
genotype. Assuming a transcript feature E is selected for phenotype D,
we use permutation testing to evaluate the signiﬁcance of causal edge
E-D. This is carried out for all genetic loci L that link to E and is
controlled for the inﬂuence of L-D. More speciﬁcally, we assess the
signiﬁcance of association between E and D by permuting E ﬁxed
under the genotype L. If gene expression remains signiﬁcantly
predictive (even when permuted while keeping the allele at L ﬁxed),
wedeterminethatEholdsadditionalinformationbeyondthatencoded
in the marker L and is likely a causal factor.
Zoom-in score
The zoom-in score is a Bayesian prioritization score that ranks all
genes within a linked region, evaluating the likelihood that each gene
is causal. It is used to pinpoint the causal gene variant responsible for
creating the linkage signal, and is applied to each of the marker
features selected. The method integrates three cues: ‘Is the gene
expression level a good predictor of drug resistance’, that is, does the
gene expression correlate with the drug resistance? ‘Is the gene ‘cis-
linked’, that is, is the gene’s expression linked to its own locus?’ and
‘How well is the sequence of the gene conserved across 19 yeast
species (Wapinski et al, 2007)?’, consistent with our intuition that
deviations from the conserved sequence are more likely to have a
causal inﬂuence. This allows us to prioritize genes within each linked
genomic region for their potential effect on the phenotype D.
Let gene g reside in genotype Lg and have an expression proﬁle Eg;
we can decompose the joint probability P(D, Eg, Lg) as follows:
PðD; Eg; LgÞ¼PðDjLg; EgÞPðEgjLgÞPðLgÞ
We calculate both P(D|Lg, Eg) and P(Eg|Lg) using least-square ﬁtting
regressionand P(Lg) based on the conservation of the codingsequence
(see Supplementary information for more details). The decomposed
probability consists of three parts. The ﬁrst term P(D|Lg, Eg) explains
the phenotype with both genotype and expression proﬁle of gene g,
suggestingghasacausaleffect.Thesecondandthirdtermsactasprior
probabilitiesthatthegenehasacausalrole,independentofthespeciﬁc
phenotype.
Statistical analysis
Camelot, the elastic net L model and linkage analysis are evaluated
with 10-fold cross-validation (n¼93–94). Elastic net L models are
derived in the samewayas Camelot models, except that only genotype
features were allowed in regression. Linkage analysis is performed
with Wilcoxon rank-sum test to scan the 526 merged markers for
genome-wide signiﬁcantlinkages(FDR¼2%,Po5.6 10
 5)(Perlstein
et al, 2007). Linear regression models are built on signiﬁcant linkages
using robust regression (robustﬁt function in Matlab). Classiﬁcation
accuracy is used to evaluate predictions of models. Growth data are
discretized into three classes according to their normalized values:
resistant to the drug, no signiﬁcant response and sensitive to the drug.
Predictions of responses to drugs were made based on the predicted
valuesfromregressionmodels.Classiﬁcationaccuracy(Acc)isdeﬁned
as the number of correct classiﬁcations divided by the number of
test data.
The signiﬁcance of the interaction between PHO84 and GPB2 alleles
isassessedbyWilcoxonrank-sumtest,wheresegregantswithboththe
PHO84-RMandGPB2-BYallelesaretreatedasonesampleandtheother
segregants as another independent sample. Enrichment of phosphate
metabolism/transport-related genes (GO annotation) in the linked
regions shown in Figure 6D was calculated using the hypergeometric
distribution. Each linked marker was expanded to 40kb for the
purposes of enrichment analysis. The linkages for PHO84 gene
expression were obtained with Wilcoxon rank-sum test (Po0.01).
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RT–PCR experiments were carried out to quantify the abundance of
the PHO84 transcript. Total RNA was prepared using the Ambion
RiboPure-Yeast kit according to the manufacturer’s instructions, with
the exception that a 10mg sample was digested twice each for 1h
at 371C with 2U DNase I. cDNA was made using the Stratagene
AfﬁnityScript kit and random primers. RT–PCR was performed with a
Chromo4 machine (BioRad) using iQ SYBR Green Supermix (BioRad)
and primers listed in Supplementary Table II. Data were scaled to
ERV25 (Pfafﬂ, 2001).
For the lowand high-phosphate conditions, overnight cultures were
washed twice with sterile distilled water and used to inoculate SC
medium containing low phosphate (250mM). After at least two
doublings, cultures were split in two and phosphate was added at
15mM ﬁnal concentration (‘high phosphate’) to one ﬂask. The
cultures were grown for a further 80min before harvesting. Phosphate
media was made using YNB–potassium phosphate (Sunrise Science)
supplemented with amino acids, glucose, ammonium sulphate and
potassium phosphate. Potassium chloride (10mM) was added to low-
phosphate media.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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